Compare Aecom (ACM) vs ADMA Biologics Inc (ADMA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aecom vs ADMA Biologics Inc — how do they compare? Aecom trades at $68.26 (market cap $8.69B), while ADMA Biologics Inc trades at $9.27 (market cap $2.13B). The key difference: Aecom is far larger — about 4.1× ADMA Biologics Inc's market cap, and Aecom pays a 1.76% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ACM | ADMA | |
|---|---|---|
Market Cap | $8.69B | $2.13B |
Sector | Industrials | Health |
52-Week High | $134.35 | $20.38 |
52-Week Low | $66.86 | $7.60 |
Enterprise Value | $10.88B | $2.20B |
Dividend Yield | 1.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM trades at $67.64, down 0.15% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.53 and P/S of 0.57, while recent earnings beat expectations in Q1 2026. Analyst consensus is bullish with a $98.83 price target, though recent news includes both contract wins and legal investigations.
The outlook for ACM is mixed: strong valuation metrics and recent contract awards support upside potential, but technical weakness and legal scrutiny pose near-term risks. Earnings growth and margin expansion remain key catalysts, while investor sentiment is cautious due to the stock's 21% decline over the past three months.
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →
